<div class="headers"><div>Figure 4 Cardiovascular death, myocardial infarction, or stroke at 3 years with ticagrelor doses pooled (purple) compared with placebo in patients withdrawn from P2Y12 inhibitor therapy within 30 days of randomization stratiﬁed by a qualifying myocardial infarction ,24 months prior to randomization (left) and ≥24 months prior to randomization (right)</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; border-bottom: 2px solid grey; text-align: left;'><p class="">Figure 4 Cardiovascular death, myocardial infarction, or stroke at 3 years with ticagrelor doses pooled (purple) compared with placebo in patients withdrawn from P2Y12 inhibitor therapy within 30 days of randomization stratiﬁed by a qualifying myocardial infarction ,24 months prior to randomization (left) and ≥24 months prior to randomization (right)</p></td>
</tr>
</tbody>
</table>
